Tags

Type your tag names separated by a space and hit enter

Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action.
J Hepatol 1998; 29(2):173-83JH

Abstract

BACKGROUND/AIMS

To investigate the impact of hepatitis B (HBV) and C (HCV) infections on hepatocellular carcinoma (HCC) in Europe.

METHODS

Five hundred and three patients with HCC, from six liver centers, were included. All 503 sera and 80 liver samples were tested for HBV DNA and HCV RNA by polymerase chain reaction. GBV-C/HGV RNA was also tested in 57 sera.

RESULTS

HBsAg and anti-HCV were detected in 19% and 40.1% of the patients, respectively. Serum and liver HBV DNA were detected in 82% and 91% of the HBsAg positive subjects. HBV DNA was also detected in the serum and liver of 33% and 47% of HBsAg negative patients. In this group, serum HBV DNA was more prevalent in anti-HBs and/or anti-HBc patients (47.9%), compared to those without any HBV marker (25.1%). HCV RNA was detected in 89% and 7% of anti-HCV positive and negative cases, respectively, HCV 1b being the most prevalent genotype (80%). Coinfection with HBV and HCV was shown in 20.4% of patients, while only 29% had neither HBV nor HCV GBV-C/HGV RNA was detected in only 4/57 sera.

CONCLUSIONS

This study offers the first large analysis of HCC in Europe, based on both serology and molecular tests. It demonstrates the major impact of HBV and HCV, but not of GBV-C/HGV, in liver carcinogenesis in Northern as well as Southern Europe. It also stresses the need to use viral genome detection in epidemiological studies when serological tests are negative.

Authors+Show Affiliations

INSERM U370 and Liver Unit, CHU Necker, Paris, France. brechot@necker.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9722197

Citation

Bréchot, C, et al. "Impact of HBV, HCV and GBV-C/HGV On Hepatocellular Carcinomas in Europe: Results of a European Concerted Action." Journal of Hepatology, vol. 29, no. 2, 1998, pp. 173-83.
Bréchot C, Jaffredo F, Lagorce D, et al. Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action. J Hepatol. 1998;29(2):173-83.
Bréchot, C., Jaffredo, F., Lagorce, D., Gerken, G., Meyer zum Büschenfelde, K., Papakonstontinou, A., ... Naoumov, N. (1998). Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action. Journal of Hepatology, 29(2), pp. 173-83.
Bréchot C, et al. Impact of HBV, HCV and GBV-C/HGV On Hepatocellular Carcinomas in Europe: Results of a European Concerted Action. J Hepatol. 1998;29(2):173-83. PubMed PMID: 9722197.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action. AU - Bréchot,C, AU - Jaffredo,F, AU - Lagorce,D, AU - Gerken,G, AU - Meyer zum Büschenfelde,K, AU - Papakonstontinou,A, AU - Hadziyannis,S, AU - Romeo,R, AU - Colombo,M, AU - Rodes,J, AU - Bruix,J, AU - Williams,R, AU - Naoumov,N, PY - 1998/8/29/pubmed PY - 1998/8/29/medline PY - 1998/8/29/entrez SP - 173 EP - 83 JF - Journal of hepatology JO - J. Hepatol. VL - 29 IS - 2 N2 - BACKGROUND/AIMS: To investigate the impact of hepatitis B (HBV) and C (HCV) infections on hepatocellular carcinoma (HCC) in Europe. METHODS: Five hundred and three patients with HCC, from six liver centers, were included. All 503 sera and 80 liver samples were tested for HBV DNA and HCV RNA by polymerase chain reaction. GBV-C/HGV RNA was also tested in 57 sera. RESULTS: HBsAg and anti-HCV were detected in 19% and 40.1% of the patients, respectively. Serum and liver HBV DNA were detected in 82% and 91% of the HBsAg positive subjects. HBV DNA was also detected in the serum and liver of 33% and 47% of HBsAg negative patients. In this group, serum HBV DNA was more prevalent in anti-HBs and/or anti-HBc patients (47.9%), compared to those without any HBV marker (25.1%). HCV RNA was detected in 89% and 7% of anti-HCV positive and negative cases, respectively, HCV 1b being the most prevalent genotype (80%). Coinfection with HBV and HCV was shown in 20.4% of patients, while only 29% had neither HBV nor HCV GBV-C/HGV RNA was detected in only 4/57 sera. CONCLUSIONS: This study offers the first large analysis of HCC in Europe, based on both serology and molecular tests. It demonstrates the major impact of HBV and HCV, but not of GBV-C/HGV, in liver carcinogenesis in Northern as well as Southern Europe. It also stresses the need to use viral genome detection in epidemiological studies when serological tests are negative. SN - 0168-8278 UR - https://www.unboundmedicine.com/medline/citation/9722197/Impact_of_HBV_HCV_and_GBV_C/HGV_on_hepatocellular_carcinomas_in_Europe:_results_of_a_European_concerted_action_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0168-8278(98)80001-9 DB - PRIME DP - Unbound Medicine ER -